Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GNLXNASDAQ:HLVXNASDAQ:MGNXNASDAQ:NRSN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGNLXGenelux$3.06+15.5%$2.59$1.60▼$5.89$115.47M-0.49190,281 shs579,660 shsHLVXHilleVax$1.85-3.6%$1.85$1.34▼$15.60$92.76M0.74446,931 shs354,921 shsMGNXMacroGenics$1.52-1.9%$1.50$0.99▼$5.77$95.90M1.66860,043 shs952,149 shsNRSNNeuroSense Therapeutics$2.38$1.33$0.51▼$2.60$32.53M1.62272,391 shs381,486 shs10 Stocks Set to Soar in Summer 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGNLXGenelux+15.47%+19.53%+27.50%-10.00%+26.97%HLVXHilleVax-3.65%-7.04%-3.14%+5.71%-87.33%MGNXMacroGenics-1.94%-14.61%-1.94%-31.53%-69.54%NRSNNeuroSense Therapeutics0.00%+32.96%+95.42%+101.69%+131.07%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGNLXGenelux1.1992 of 5 stars3.60.00.00.02.60.00.0HLVXHilleVax3.2508 of 5 stars3.03.00.00.03.23.31.3MGNXMacroGenics3.8076 of 5 stars3.21.00.04.42.02.50.6NRSNNeuroSense Therapeutics2.1868 of 5 stars3.53.00.00.02.21.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGNLXGenelux 3.20Buy$17.75480.07% UpsideHLVXHilleVax 2.00Hold$3.0062.16% UpsideMGNXMacroGenics 2.40Hold$5.71275.94% UpsideNRSNNeuroSense Therapeutics 3.00Buy$14.00488.24% UpsideCurrent Analyst Ratings BreakdownLatest NRSN, MGNX, HLVX, and GNLX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/20/2025MGNXMacroGenicsB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$5.00 ➝ $3.005/14/2025MGNXMacroGenicsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$8.00 ➝ $3.005/14/2025MGNXMacroGenicsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetHold ➝ Hold$6.00 ➝ $5.005/12/2025NRSNNeuroSense TherapeuticsD Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/12/2025NRSNNeuroSense TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$14.005/8/2025GNLXGeneluxBenchmarkSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSpeculative Buy ➝ Speculative Buy$25.00 ➝ $23.003/31/2025GNLXGeneluxHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.00 ➝ $30.003/31/2025HLVXHilleVaxHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$2.00 ➝ $2.003/25/2025GNLXGeneluxHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.00 ➝ $30.003/25/2025MGNXMacroGenicsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$4.00 ➝ $2.00(Data available from 6/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGNLXGenelux$8K14,433.64N/AN/A$0.73 per share4.19HLVXHilleVaxN/AN/AN/AN/A$5.48 per shareN/AMGNXMacroGenics$152.43M0.63N/AN/A$2.46 per share0.62NRSNNeuroSense TherapeuticsN/AN/AN/AN/A($0.14) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGNLXGenelux-$28.30M-$0.88N/AN/AN/AN/A-105.05%-80.16%8/13/2025 (Estimated)HLVXHilleVax-$123.57M-$2.15N/AN/AN/AN/A-67.27%-51.99%8/14/2025 (Estimated)MGNXMacroGenics-$9.06M-$0.89N/AN/AN/A-69.07%-89.42%-38.57%8/5/2025 (Estimated)NRSNNeuroSense Therapeutics-$11.28M-$0.54N/A∞N/AN/AN/A-590.79%6/24/2025 (Estimated)Latest NRSN, MGNX, HLVX, and GNLX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/24/2025Q1 2025NRSNNeuroSense Therapeutics-$0.13N/AN/AN/AN/AN/A5/13/2025Q1 2025MGNXMacroGenics-$0.61-$0.65-$0.04-$0.65$9.59 million$13.19 million5/8/2025Q1 2025GNLXGenelux-$0.24-$0.21+$0.03-$0.21N/AN/A5/8/2025Q1 2025HLVXHilleVax-$0.37-$0.12+$0.25-$0.12N/AN/A4/7/2025Q4 2024NRSNNeuroSense Therapeutics-$0.12-$0.06+$0.06-$0.06N/AN/A3/28/2025Q4 2024GNLXGenelux-$0.17-$0.26-$0.09-$0.26N/AN/A3/28/2025Q4 2024HLVXHilleVax-$0.33-$0.35-$0.02-$0.68N/AN/A3/20/2025Q4 2024MGNXMacroGenics-$0.23-$0.25-$0.02-$0.25$34.17 million$49.40 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGNLXGeneluxN/AN/AN/AN/AN/AHLVXHilleVaxN/AN/AN/AN/AN/AMGNXMacroGenicsN/AN/AN/AN/AN/ANRSNNeuroSense TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGNLXGeneluxN/A6.476.47HLVXHilleVaxN/A14.2514.25MGNXMacroGenicsN/A3.753.69NRSNNeuroSense TherapeuticsN/A0.21N/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGNLXGenelux37.33%HLVXHilleVax86.42%MGNXMacroGenics96.89%NRSNNeuroSense Therapeutics1.04%Insider OwnershipCompanyInsider OwnershipGNLXGenelux9.30%HLVXHilleVax24.90%MGNXMacroGenics13.00%NRSNNeuroSense Therapeutics27.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGNLXGenelux1037.74 million31.33 millionNot OptionableHLVXHilleVax2050.14 million14.39 millionNot OptionableMGNXMacroGenics43063.09 million55.67 millionOptionableNRSNNeuroSense Therapeutics1013.67 million9.92 millionNot OptionableNRSN, MGNX, HLVX, and GNLX HeadlinesRecent News About These CompaniesTop Nasdaq Companies by Market Cap Ranked by KalkineJune 7, 2025 | kalkinemedia.comNeurosense, awaiting Canada approval, scales PrimeC productionMay 15, 2025 | alsnewstoday.comD. Boral Capital Initiates Coverage of NeuroSense Therapeutics (NRSN) with Buy RecommendationMay 14, 2025 | msn.comWhy This Nano-Cap Stock Might Skyrocket To $14, Per Analyst InsightsMay 12, 2025 | benzinga.comNeuroSense Therapeutics Announces Successful Completion of Commercial Manufacturing Scale-Up for PrimeC in Preparation for Potential Canadian Market LaunchMay 7, 2025 | prnewswire.comNeuroSense Therapeutics Advances ALS Treatment and Strategic PartnershipApril 24, 2025 | tipranks.comNeuroSense Therapeutics Releases Letter to Shareholders Outlining Clinical Progress, Regulatory Strategy, and Partnership UpdateApril 24, 2025 | prnewswire.comNeuroSense Therapeutics Presents Promising Phase 2b Data on PrimeC for ALS at AAN MeetingApril 10, 2025 | sohu.comNeuroSense Therapeutics Reports Year-End 2024 Financial Results and Provides Business UpdatesApril 10, 2025 | sohu.comNeuroSense Therapeutics Announces Transformative Phase 2b MicroRNA Data, Highlighting PrimeC's Promise as a Disease-Modifying ALS TreatmentApril 9, 2025 | prnewswire.comNeuroSense Therapeutics Reports Year End 2024 Financial Results and Provides Business UpdatesApril 7, 2025 | prnewswire.comNeuroSense Therapeutics to Present New Data from PrimeC's Phase 2b Trial in ALS at the Annual American Academy of Neurology MeetingApril 4, 2025 | prnewswire.comMarket Alert: NeuroSense Therapeutics Advances Toward Early Canadian Commercialization of ALS DrugMarch 20, 2025 | businesswire.comNeuroSense Advances PrimeC Commercialization in CanadaMarch 19, 2025 | tipranks.comPESG Releases Report on NeuroSense Therapeutics: Groundbreaking ALS Therapy Signals Massive Potential Opportunity in Billion Dollar Treatment LandscapeMarch 17, 2025 | businesswire.comLife Saving Innovation in Neurodegenerative Disease Treatment: An Interview with Alon Ben-Noon, CEO & Founder of NeuroSense TherapeuticsMarch 12, 2025 | techbullion.comNeuroSense Therapeutics Reports Positive Phase 2b Study Results for ALS TreatmentFebruary 19, 2025 | tipranks.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Neurosense Therapeutics Ltd. (NRSN), Elevance Health (ELV) and Genmab (GMAB)February 4, 2025 | markets.businessinsider.comNeuroSense regains Nasdaq complianceJanuary 8, 2025 | markets.businessinsider.comNeurosense plans to license rights to advance PrimeC in certain regionsJanuary 7, 2025 | alsnewstoday.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNRSN, MGNX, HLVX, and GNLX Company DescriptionsGenelux NASDAQ:GNLX$3.06 +0.41 (+15.47%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$3.04 -0.02 (-0.49%) As of 06/13/2025 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer. The company is also developing V2ACT Immunotherapy for treating pancreatic cancer. Genelux Corporation has a licensing agreement with ELIAS Animal Health, LLC for V-VET1, a clinical stage animal health product candidate. The company was incorporated in 2001 and is headquartered in Westlake Village, California.HilleVax NASDAQ:HLVX$1.85 -0.07 (-3.65%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$1.85 0.00 (0.00%) As of 06/13/2025 04:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc. and changed its name to HilleVax, Inc. in February 2021. HilleVax, Inc. was founded in 2019 and is headquartered in Boston, Massachusetts.MacroGenics NASDAQ:MGNX$1.52 -0.03 (-1.94%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$1.53 +0.01 (+0.66%) As of 06/13/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.NeuroSense Therapeutics NASDAQ:NRSN$2.38 0.00 (0.00%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$2.38 +0.00 (+0.21%) As of 06/13/2025 05:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/09 - 06/13 Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Ignore the Noise—Samsara Stock Is Still a Strong Buy Fastenal Stock After Split: Poised for 5 More Years of Gains Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
